The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.
Affiliation
CRC Department of Medical Oncology, Christie Hospital, Manchester.Issue Date
1996-04
Metadata
Show full item recordAbstract
This is a phase I/II study of the GM-CSF/IL-3 fusion protein (PIXY321. Patients were treated with PIXY321 at a daily subcutaneous dose of 500, 750 and 1000 micrograms/m2 for 14 d. Side-effects were mild and consisted mainly of injection-site reactions and constitutional symptoms. A biphasic modest increase of white blood count (2-5-fold) and platelets (1-1.5 fold) was seen, accompanied by an increased bone marrow cellularity and an increase in circulating progenitors. Colony-forming cells in the blood rose to a median of 184 granulocyte/macrophage-colony forming cells (GM-CFC)/ml, eight Mix-CFC/ml, 250 burst forming units-erythroid (BFU-E)/ml and 140 CFU-mega-karyocytes/ml, corresponding to a 10-, 2.5, 8- and 30-fold increase respectively. When seeded for long-term culture on irradiated bone marrow stroma, the mobilized cells were not able to sustain haemopoiesis in vitro to the same degree as bone marrow. Taken together these results indicate that PIXY321 has a biological effect in humans more similar to that of IL-3 than to that of GM-CSF.Citation
The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. 1996, 93 (1):6-12 Br. J. Haematol.Journal
British Journal of HaematologyDOI
10.1046/j.1365-2141.1996.4731015.xPubMed ID
8611477Type
ArticleLanguage
enISSN
0007-1048ae974a485f413a2113503eed53cd6c53
10.1046/j.1365-2141.1996.4731015.x
Scopus Count
Related articles
- Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
- Authors: Broxmeyer HE, Benninger L, Cooper S, Hague N, Benjamin RS, Vadhan-Raj S
- Issue date: 1995 Apr
- Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.
- Authors: Bishop MR, Jackson JD, O'Kane-Murphy B, Schmit-Pokorny K, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Garrison L, Kessinger A
- Issue date: 1996 Sep
- Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
- Authors: Lemoli RM, Gulati SC
- Issue date: 1993 Sep
- Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
- Authors: Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S
- Issue date: 1995 Dec
- Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
- Authors: Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L
- Issue date: 1997 Apr